<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02061202</url>
  </required_header>
  <id_info>
    <org_study_id>GCO 12-1565</org_study_id>
    <secondary_id>K23HL119351</secondary_id>
    <nct_id>NCT02061202</nct_id>
  </id_info>
  <brief_title>Inhaled Mometasone to Reduce Painful Episodes in Patients With Sickle Cell Disease</brief_title>
  <acronym>IMPROVE</acronym>
  <official_title>Inhaled Mometasone to Promote Reduction in Vasoocclusive Events</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jeffrey Glassberg</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Heart, Lung, and Blood Institute (NHLBI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Icahn School of Medicine at Mount Sinai</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The proposed research is designed to test the global hypothesis that inhaled corticosteroids
      (ICS), a therapy developed to treat asthma, will prevent vasoocclusive painful episodes in
      adults with Sickle Cell Disease (SCD) who wheeze, but do not meet criteria for a diagnosis of
      asthma. The specific aims of this proposal are 1) Conduct a feasibility study - a randomized
      controlled trial of ICS for adults with SCD who do not meet criteria for a diagnosis of
      asthma but report recurrent cough or wheezing, 2) Measure the effects of ICS on biological
      correlates of pulmonary inflammation (as determined by exhaled nitric oxide) and vascular
      injury (as determined by sVCAM) in SCD, and 3) Compare properties of traditional and Bayesian
      adaptive clinical trial design for therapeutic trials in SCD in preparation for designing a
      definitive trial of ICS. These aims have the potential to 1) change the standard of care for
      individuals with SCD and recurrent cough or wheeze, 2) provide insight into the pathogenesis
      of non-asthmatic wheezing in SCD and its response to treatment, 3) explore the suitability of
      innovative clinical trial designs to overcome the challenges that have hindered therapeutic
      innovation for SCD.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2014</start_date>
  <completion_date type="Actual">November 2017</completion_date>
  <primary_completion_date type="Actual">November 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants Who Completed Follow up</measure>
    <time_frame>at 2 years</time_frame>
    <description>Feasibility is determined by calculating the proportion of randomized participants who complete follow up and a minimum of 30 pain diaries with good adherence to the study medication vs. the number enrolled.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Exhaled Nitric Oxide (eNO)</measure>
    <time_frame>Before ICS therapy begins and at 8 weeks post enrollment</time_frame>
    <description>Change in effects of inhaled corticosteroids (ICS) as measured by exhaled nitric oxide levels, which is the primary marker of pulmonary inflammation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Soluble Vascular Cell Adhesion Molecule (sVCAM) Level</measure>
    <time_frame>Before ICS therapy begins and at 8 weeks post enrollment</time_frame>
    <description>Mean Change in effects of inhaled corticosteroids vascular injury, assessed by biomarker sVCAM as a surrogate for vascular injury.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Adult Sickle Cell Quality of Life Measurement Information System (ASCQ-Me)</measure>
    <time_frame>baseline and week 20</time_frame>
    <description>Mean changes in ASCQ-Me (NHLBI developed a patient-reported Sickle Cell Disease (SCD) quality of life measurement tool) pain impact, at week 20 as compared to baseline. A reduction change on a 100-point scale indicated improved quality of life. ASCQ-Me uses a T-score metric (0-100) in which 50 is the mean of the reference population and 10 is the standard deviation (SD) of that population.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Medication Adherence Report Scale</measure>
    <time_frame>20 weeks</time_frame>
    <description>The medication adherence report scale for asthma is a 10 question tool scored between 0 and 5, with full scale from 0 to 25, with higher scores indicating greater adherence</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in the Numerical Rating Scale (NRS) for Pain</measure>
    <time_frame>baseline and 20 weeks</time_frame>
    <description>Mean change in patient reported pain NRS score, full scale range 0- 10, higher score indicate more pain</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Asthma Control Test</measure>
    <time_frame>8 weeks</time_frame>
    <description>Asthma control test, total score from 0-25, with higher score indicating more symptoms</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Admissions or Visits to the Hospital</measure>
    <time_frame>baseline through 8 weeks</time_frame>
    <description>Number of times participant visited the Emergency Department (ED) or was admitted to the hospital</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Reticulocytes Count</measure>
    <time_frame>baseline and 8 weeks</time_frame>
    <description>Mean change in reticulocytes count - the number of new red blood cells.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in FEV1/FVC</measure>
    <time_frame>baseline and 8 weeks</time_frame>
    <description>Mean change in FEV1/FVC at 8 weeks compared to baseline</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">54</enrollment>
  <condition>Sickle Cell Disease</condition>
  <arm_group>
    <arm_group_label>Mometasone Furoate</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1 puff daily (220mcg) for 16 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>1 puff daily for 16 weeks. Training inhaler that does not contain any medication (placebo).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mometasone Furoate</intervention_name>
    <description>inhaled cortico-steroid (ICS) with a dosage of 220mcg once daily for 16 weeks</description>
    <arm_group_label>Mometasone Furoate</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>placebo training inhaler with the same instructions as the experimental group.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 15 or older

          -  Sever SCD phenotypes (Hb SS and Sβthalassemia0)

          -  A positive response to cough/wheeze questions

        Exclusion Criteria:

          -  Patient carries a physician diagnosis of asthma

          -  Patient is prescribed asthma medications

          -  Patient is currently having a painful crisis (as defined by validated pain diary
             questions)

          -  Patient has acute respiratory symptoms

          -  Known hypersensitivity to milk proteins

          -  Meets criteria for our operational diagnosis of asthma

          -  More than 15 ED visits for pain over the preceding 12 months

          -  Admitted or discharged from the hospital for SCD pain within the last 7 days
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>15 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jeffrey Glassberg, MD, MA</last_name>
    <role>Principal Investigator</role>
    <affiliation>Icahn School of Medicine at Mount Sinai</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Icahn School of Medicine at Mount Sinai</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2019</verification_date>
  <study_first_submitted>January 14, 2014</study_first_submitted>
  <study_first_submitted_qc>February 11, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 12, 2014</study_first_posted>
  <results_first_submitted>October 26, 2018</results_first_submitted>
  <results_first_submitted_qc>March 8, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">March 11, 2019</results_first_posted>
  <last_update_submitted>March 8, 2019</last_update_submitted>
  <last_update_submitted_qc>March 8, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">March 11, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Icahn School of Medicine at Mount Sinai</investigator_affiliation>
    <investigator_full_name>Jeffrey Glassberg</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <keyword>Sickle Cell Disease</keyword>
  <keyword>Pain Crisis</keyword>
  <keyword>Painful Crisis</keyword>
  <keyword>Sickle Pain</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anemia, Sickle Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mometasone Furoate</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>November 18, 2015</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/02/NCT02061202/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Recruitment began in February 2014, with first enrollment in March 2014, and last enrollment in October 2016</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Mometasone Furoate</title>
          <description>1 puff daily (220mcg) for 16 weeks</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>1 puff daily for 16 weeks. Training inhaler that does not contain any medication (placebo)</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="36"/>
                <participants group_id="P2" count="18"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="35"/>
                <participants group_id="P2" count="17"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>1 participant in each group was lost to follow up prior to data collection and excluded from analyses.</population>
      <group_list>
        <group group_id="B1">
          <title>Mometasone Furoate</title>
          <description>1 puff daily (220mcg) for 16 weeks</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>1 puff daily for 16 weeks. Training inhaler that does not contain any medication (placebo)</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="35"/>
            <count group_id="B2" value="17"/>
            <count group_id="B3" value="52"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="35"/>
                    <count group_id="B2" value="17"/>
                    <count group_id="B3" value="52"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="30" spread="8.56"/>
                    <measurement group_id="B2" value="36" spread="9.81"/>
                    <measurement group_id="B3" value="32" spread="9.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="35"/>
                    <count group_id="B2" value="17"/>
                    <count group_id="B3" value="52"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="24"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race and Ethnicity Not Collected</title>
          <population>Race and Ethnicity were not collected from any participant.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                    <count group_id="B2" value="0"/>
                    <count group_id="B3" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants Who Completed Follow up</title>
        <description>Feasibility is determined by calculating the proportion of randomized participants who complete follow up and a minimum of 30 pain diaries with good adherence to the study medication vs. the number enrolled.</description>
        <time_frame>at 2 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Mometasone Furoate</title>
            <description>1 puff daily (220mcg) for 16 weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>1 puff daily for 16 weeks. Training inhaler that does not contain any medication (placebo)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Who Completed Follow up</title>
          <description>Feasibility is determined by calculating the proportion of randomized participants who complete follow up and a minimum of 30 pain diaries with good adherence to the study medication vs. the number enrolled.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="36"/>
                <count group_id="O2" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35"/>
                    <measurement group_id="O2" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Exhaled Nitric Oxide (eNO)</title>
        <description>Change in effects of inhaled corticosteroids (ICS) as measured by exhaled nitric oxide levels, which is the primary marker of pulmonary inflammation.</description>
        <time_frame>Before ICS therapy begins and at 8 weeks post enrollment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Mometasone Furoate</title>
            <description>1 puff daily (220mcg) for 16 weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>1 puff daily for 16 weeks. Training inhaler that does not contain any medication (placebo)</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Exhaled Nitric Oxide (eNO)</title>
          <description>Change in effects of inhaled corticosteroids (ICS) as measured by exhaled nitric oxide levels, which is the primary marker of pulmonary inflammation.</description>
          <units>ppb</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="35"/>
                <count group_id="O2" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.63" lower_limit="-2.51" upper_limit="3.77"/>
                    <measurement group_id="O2" value="2.71" lower_limit="0.48" upper_limit="5.90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Soluble Vascular Cell Adhesion Molecule (sVCAM) Level</title>
        <description>Mean Change in effects of inhaled corticosteroids vascular injury, assessed by biomarker sVCAM as a surrogate for vascular injury.</description>
        <time_frame>Before ICS therapy begins and at 8 weeks post enrollment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Mometasone Furoate</title>
            <description>1 puff daily (220mcg) for 16 weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>1 puff daily for 16 weeks. Training inhaler that does not contain any medication (placebo)</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Soluble Vascular Cell Adhesion Molecule (sVCAM) Level</title>
          <description>Mean Change in effects of inhaled corticosteroids vascular injury, assessed by biomarker sVCAM as a surrogate for vascular injury.</description>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="35"/>
                <count group_id="O2" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-182.47" spread="785.21"/>
                    <measurement group_id="O2" value="170.25" spread="182.39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Adult Sickle Cell Quality of Life Measurement Information System (ASCQ-Me)</title>
        <description>Mean changes in ASCQ-Me (NHLBI developed a patient-reported Sickle Cell Disease (SCD) quality of life measurement tool) pain impact, at week 20 as compared to baseline. A reduction change on a 100-point scale indicated improved quality of life. ASCQ-Me uses a T-score metric (0-100) in which 50 is the mean of the reference population and 10 is the standard deviation (SD) of that population.</description>
        <time_frame>baseline and week 20</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Mometasone Furoate</title>
            <description>1 puff daily (220mcg) for 16 weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>1 puff daily for 16 weeks. Training inhaler that does not contain any medication (placebo)</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Adult Sickle Cell Quality of Life Measurement Information System (ASCQ-Me)</title>
          <description>Mean changes in ASCQ-Me (NHLBI developed a patient-reported Sickle Cell Disease (SCD) quality of life measurement tool) pain impact, at week 20 as compared to baseline. A reduction change on a 100-point scale indicated improved quality of life. ASCQ-Me uses a T-score metric (0-100) in which 50 is the mean of the reference population and 10 is the standard deviation (SD) of that population.</description>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="35"/>
                <count group_id="O2" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.8" spread="22.7"/>
                    <measurement group_id="O2" value="6.9" spread="24.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Medication Adherence Report Scale</title>
        <description>The medication adherence report scale for asthma is a 10 question tool scored between 0 and 5, with full scale from 0 to 25, with higher scores indicating greater adherence</description>
        <time_frame>20 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Mometasone Furoate</title>
            <description>1 puff daily (220mcg) for 16 weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>1 puff daily for 16 weeks. Training inhaler that does not contain any medication (placebo)</description>
          </group>
        </group_list>
        <measure>
          <title>The Medication Adherence Report Scale</title>
          <description>The medication adherence report scale for asthma is a 10 question tool scored between 0 and 5, with full scale from 0 to 25, with higher scores indicating greater adherence</description>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="35"/>
                <count group_id="O2" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.7" spread="2.25"/>
                    <measurement group_id="O2" value="17.1" spread="1.78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in the Numerical Rating Scale (NRS) for Pain</title>
        <description>Mean change in patient reported pain NRS score, full scale range 0- 10, higher score indicate more pain</description>
        <time_frame>baseline and 20 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Mometasone Furoate</title>
            <description>1 puff daily (220mcg) for 16 weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>1 puff daily for 16 weeks. Training inhaler that does not contain any medication (placebo)</description>
          </group>
        </group_list>
        <measure>
          <title>Change in the Numerical Rating Scale (NRS) for Pain</title>
          <description>Mean change in patient reported pain NRS score, full scale range 0- 10, higher score indicate more pain</description>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="35"/>
                <count group_id="O2" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.09" spread="2.55"/>
                    <measurement group_id="O2" value="2.82" spread="2.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Asthma Control Test</title>
        <description>Asthma control test, total score from 0-25, with higher score indicating more symptoms</description>
        <time_frame>8 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Mometasone Furoate</title>
            <description>1 puff daily (220mcg) for 16 weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>1 puff daily for 16 weeks. Training inhaler that does not contain any medication (placebo)</description>
          </group>
        </group_list>
        <measure>
          <title>Asthma Control Test</title>
          <description>Asthma control test, total score from 0-25, with higher score indicating more symptoms</description>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="35"/>
                <count group_id="O2" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.7" spread="2.25"/>
                    <measurement group_id="O2" value="17.1" spread="1.78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Admissions or Visits to the Hospital</title>
        <description>Number of times participant visited the Emergency Department (ED) or was admitted to the hospital</description>
        <time_frame>baseline through 8 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Mometasone Furoate</title>
            <description>1 puff daily (220mcg) for 16 weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>1 puff daily for 16 weeks. Training inhaler that does not contain any medication (placebo)</description>
          </group>
        </group_list>
        <measure>
          <title>Admissions or Visits to the Hospital</title>
          <description>Number of times participant visited the Emergency Department (ED) or was admitted to the hospital</description>
          <units>Events</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="35"/>
                <count group_id="O2" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>ED visits</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.97" spread="1.52"/>
                    <measurement group_id="O2" value="1.12" spread="1.87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Observation admits</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.37" spread="0.77"/>
                    <measurement group_id="O2" value="0.59" spread="1.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Admissions</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.37" spread="0.77"/>
                    <measurement group_id="O2" value="0.47" spread="1.23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Reticulocytes Count</title>
        <description>Mean change in reticulocytes count - the number of new red blood cells.</description>
        <time_frame>baseline and 8 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Mometasone Furoate</title>
            <description>1 puff daily (220mcg) for 16 weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>1 puff daily for 16 weeks. Training inhaler that does not contain any medication (placebo)</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Reticulocytes Count</title>
          <description>Mean change in reticulocytes count - the number of new red blood cells.</description>
          <units>10^3 cells/μL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="35"/>
                <count group_id="O2" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.15" spread="0.39"/>
                    <measurement group_id="O2" value="0.07" spread="0.52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in FEV1/FVC</title>
        <description>Mean change in FEV1/FVC at 8 weeks compared to baseline</description>
        <time_frame>baseline and 8 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Mometasone Furoate</title>
            <description>1 puff daily (220mcg) for 16 weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>1 puff daily for 16 weeks. Training inhaler that does not contain any medication (placebo)</description>
          </group>
        </group_list>
        <measure>
          <title>Change in FEV1/FVC</title>
          <description>Mean change in FEV1/FVC at 8 weeks compared to baseline</description>
          <units>ratio</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="35"/>
                <count group_id="O2" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.71" spread="3.42"/>
                    <measurement group_id="O2" value="-1.41" spread="3.39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>2 years</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Mometasone Furoate</title>
          <description>1 puff daily (220mcg) for 16 weeks</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>1 puff daily for 16 weeks. Training inhaler that does not contain any medication (placebo)</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>CTCAE (Unspecified)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="35"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Hoarseness of voice</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="35"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Thrush</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="35"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Sore Throat</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="35"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Jeffrey Glassberg</name_or_title>
      <organization>Icahn School of Medicine at Mount Sinai</organization>
      <phone>212-241-3650</phone>
      <email>jeffrey.glassberg@mountsinai.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

